Figure 3

Quiescent CD4⁺T-cells from Aicardi-Goutières Syndrome patients, with inactivating mutation of SAMHD1 (AGS-5), display a Vpx-independent susceptibility to HIV-1 infection. a. Impact of Vpx treatment on susceptibility to HIV-CMV-EGFP infection of quiescent CD4⁺ T-cells (CD69- HLA-DR-) and CD14⁺ monocytes from individuals with heterozygous AGS-5 SAMHD1^-/+ mutation (n = 2). PBMCs were treated 12 h with VLP-Mock or VLP-Vpx then infected with HIV-CMV-EGFP or left uninfected (control). Proportions of EGFP positive quiescent CD4⁺ T-cells were assessed 4 days post infection. b. PBMCs from AGS-5 SAMHD1^-/- patients were treated and analyzed as in a. (n = 4). c. Impact of SAMHD1 homozygous mutation on permissivity to HIV-CMV-EGFP infection of CD4⁺ T-cell (left panel) and monocytes (right panel). Results are expressed as a fold increase of GFP positive cells among quiescent CD4⁺ T-cells, comparing SAMHD1^-/- patients to SAMHD1^-/+ individuals. d. Effect of Vpx treatment on the permissiveness of quiescent CD4⁺ T-cell (left panel) and monocytes (right panel) derived from SAMHD1^-/- patients (n = 3) and SAMHD1^-/+ (n = 1) to HIV-CMV-EGFP. Results are presented as fold increase comparing the percentage of GFP positive cells in VLP-Vpx to VLP-Mock treated samples.